Lisa Ray Highlights Chemotherapy-Induced Early Menopause and Fertility Challenges

ରାଜନୀତି

ବିଜୟଙ୍କ ନେତୃତ୍ୱାଧୀନ ତାମିଲନାଡୁ ମେଣ୍ଟକୁ ମିଳିବ ନୂଆ ନାଁ, ତିଆରି...

September 07, 2026

ହର୍ମୁଜ୍‌ ପ୍ରଣାଳୀ ବାହାରେ ‘ଏକ୍ସକ୍ଲୁଜନ୍ ଜୋନ୍’ ଘୋଷଣା କରିବ ଇରାନ,...

September 07, 2026

‘ନ୍ୟୁ ମେକ୍ସିକୋ’ ହେବ ‘ନ୍ୟୁ ଆମେରିକା’? ଟ୍ରମ୍ପଙ୍କ ମ୍ୟାପ୍ ପୋଷ୍ଟକୁ...

September 07, 2026

ଖେଳ

ୟୁଏସ୍‌ ଓପନ୍‌ରେ ଭାରତକୁ ଝଟକା: ଭାମ୍ବ୍ରି-ଚନ୍ଦ୍ରଶେଖର ବିଦା, ଦ୍ୱିତୀୟ ରାଉଣ୍ଡରେ...

September 06, 2026

US Open Day 8: ସାବାଲେଙ୍କା-ଆଲକାରାଜଙ୍କ ଉପରେ ନଜର, କ୍ୱାର୍ଟର...

September 06, 2026

MS ଧୋନିଙ୍କ IPL ଭବିଷ୍ୟତ ନେଇ ବଡ଼ ଖୁଲାସା, କ’ଣ...

September 05, 2026

ଡ୍ରେସିଂ ରୁମ୍‌ ବ୍ୟବହାରକୁ ନେଇ ଚିନ୍ତା: ରିଜୱାନ୍ ଓ ଇମାମ୍‌ଙ୍କୁ...

September 05, 2026

Lisa Ray Highlights Chemotherapy-Induced Early Menopause and Fertility Challenges

Actor Lisa Ray revealed that chemotherapy pushed her into early menopause at 37, shedding light on fertility and hormonal issues many young cancer survivors face. Experts stress early counselling and fertility preservation strategies are crucial before treatment begins.

Published by Somesh | February 18, 2026

Actor Lisa Ray’s revelation that chemotherapy induced early menopause at the age of 37 has sparked a vital conversation on an often-overlooked aspect of cancer treatment. Diagnosed with multiple myeloma in 2009, Ray spoke about the emotional and physical challenges of losing fertility and experiencing menopause unexpectedly, highlighting a gap in survivorship care.

Medical experts explain that chemotherapy, while targeting rapidly dividing cancer cells, can also damage ovarian cells, reduce egg reserves, and in some cases trigger temporary or permanent menopause. Women over 35–40, those undergoing longer treatment durations, or receiving certain drugs like alkylating agents are at higher risk.

Fortunately, protective strategies exist if discussed early. Fertility preservation options include egg or embryo freezing, ovarian tissue freezing, and the use of GnRH analogues to temporarily suppress ovarian function during chemotherapy. In cases where pelvic radiation is planned, ovarian transposition may also be considered. While no method guarantees prevention, early planning significantly improves outcomes.

Chemotherapy-induced menopause, often called “chemopause,” remains under-discussed. During diagnosis, the primary focus is survival, and reproductive or hormonal concerns may feel secondary. Social stigma around discussing reproductive health further contributes to the lack of awareness.

Hormone replacement therapy (HRT) can alleviate menopausal symptoms and protect bone and cardiovascular health but must be individualized. In hormone-sensitive cancers, HRT is generally avoided, while survivors without hormone-driven cancers may consider it under medical guidance.

Ray’s candid disclosure underscores that surviving cancer involves more than treatment success. Informed discussions about fertility, symptom management, and long-term hormonal health are essential for improving the quality of life for women undergoing chemotherapy.